Reactogenicity and Antigenicity of the Rhesus Rotavirus Vaccine in Venezuelan Children

Pérez‐Schael, Irene; Gonzalez, Marino; Daoud, Naimeh; Pérez, Mireya; Soro, Ingrid; García, Doris; Daoud, Georgette; Kapikian, Albert Z.; Flores, Jorge

doi:10.1093/infdis/155.2.334

Cited by 42 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to IgG, IgA and IgM do not cross the placenta, and the rotavirus-specific prevaccination GMT by IgA and IgM ELISAs remained stable in the two age groups. It should be noted that the seroresponse rate of 14% in the placebo recipients is similar to the rate of 15% found in the placebo recipients in a previous study in Venezuela (27). Rotavirus infection is endemic throughout the year in Venezuela.…”

supporting

confidence: 83%

“…Likewise, a study of 14 children 5 to 20 months of age showed seroresponse rates of 91 to 100% and 86% by neutralization assays and the CF test, respectively (22). In contrast, a study that included younger infants 1 to 4 months of age showed that the neutralization assay appeared to be more efficient than CF (71 versus 45%) (27). A study of neonates showed that the IgA assay was more efficient than the neutralization assay and the CF test (64 versus 10 and 0%, respectively) (5).…”

Section: Discussionmentioning

confidence: 98%

“…VOL. 27,1989 on September 3, 2020 by guest http://jcm.asm.org/ Downloaded from Although several studies with bovine rotavirus vaccine strains (RIT 4237 and WC3) have been done, most have used only one assay to test for seroresponses (1,2,31,33). One exception is a study in which 25 2-year-old children were given the RIT 4237 bovine strain (32).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates

et al. 1989

View full text Add to dashboard Cite

In a phase 1 study to evaluate human-rhesus rotavirus reassortant vaccines, 116 infants 1 to 5 months of age received one of the following five preparations: the serotype 1 reassortant, the serotype 2 reassortant, rhesus rotavirus (serotype 3), a bivalent preparation (serotypes 1 and 3), or a placebo. Seroresponses to the different vaccines were measured by plaque reduction neutralization assay (PRNA); rotavirus-specific immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays (ELISAs); and complement fixation (CF). The seroresponse rate, calculated by using a fourfold or greater antibody rise by any assay, was similar in the four vaccine groups (83 to 96%). When the data from all the vaccinees were pooled, IgA ELISA, IgG ELISA, and PRNA were comparable in detecting seroresponses (67, 62, and 70%, respectively) and more efficient than IgM ELISA (53%) and CF (44%). When the vaccinees were analyzed by age, the overall seroresponse rates were the same for infants 1 to 2 and 3 to 5 months old (90%). The IgA ELISA and PRNA were the most efficient for detecting antibody rises in both age groups. IgG ELISA was among the least efficient methods for detecting antibody rises in the younger age group but among the most efficient in the older age group (44 versus 78%). CF was among the least efficient methods in both age groups but was significantly better in the older age group than in the younger age group (54 versus 21%). Our findings show that ELISA, in particular rotavirus-specific IgA ELISA, is a sensitive indicator of vaccine takes in 1-to 5-month-old infants, the target population for vaccination. The ELISA should also be very useful in demonstrating natural rotavirus infections in field studies in which a stool specimen from a diarrheal episode is not always available. The ELISA has the advantages of being easier and quicker and requiring less serum than PRNA, but it does not give serotype-specific information about the immune response. * Corresponding author. tant human rotavirus serotypes are represented by the reassortants (serotypes 1, 2, and 4) and RRV (serotype 3). An integral part of early trials with these different rotavirus vaccine candidates is the evaluation of their immunogenicity. In this study, serologic responses in 1to 5-month-old

show abstract

supporting

confidence: 83%

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates

et al. 1989

View full text Add to dashboard Cite

show abstract

“…In addition, RRV is G type 3. Similar to the bovine strains, oral inoculation of infants and young children with RRV induced rotavirus-specific IgG, IgA and IgM in serum, rotavirusspecific IgA in feces, and RRV-but not G1-specific neutralizing antibodies in serum (Losonsky et al, 1986b(Losonsky et al, , 1988Anderson et al, 1986;Perez-Schael et al, 1987;Rennels et al, 1987;Christy et al, 1988). Similar to WC3, oral inoculation of RRV in infants and young children inconsistently protected against rotavirus disease in developed countries (Rennels et al, 1986(Rennels et al, , 1990Wright et al, 1987;Christy et al, 1988;Vesikari et al, 1990;Gothefors et al, 1990).…”

Section: E Response To and Protection Against Disease By Active Immmentioning

confidence: 98%

Rotaviruses: Immunological Determinants of Protection Against Infection and Disease

Offit

1994

Advances in Virus Research

View full text Add to dashboard Cite

“…A 10 4 PFU dose of vaccine was shown to be safe and immunogenic in the target population of 2-to 5-month-old infants, although in some studies, approximately one-third of infants developed a transient, low-grade fever 3 to 4 days after vaccination (1,22,75,76,78,80,113,135,146). At this dose, antibody responses were detected in 70% or more of infants and vaccine virus was isolated from stool by amplification in cell culture in approximately 59 to 75% of infants (90,113). Neutralizing-antibody responses were predominantly homotypic in this young age group (54,90).…”

Section: Rhesus Rotavirus Vaccine Strain Mmu18006mentioning

confidence: 99%

Rotavirus vaccines: an overview

1996

View full text Add to dashboard Cite

Rotavirus vaccine development has focused on the delivery of live attenuated rotavirus strains by the oral route. The initial "Jennerian" approach involving bovine (RIT4237, WC3) or rhesus (RRV) rotavirus vaccine candidates showed that these vaccines were safe, well tolerated, and immunogenic but induced highly variable rates of protection against rotavirus diarrhea. The goal of a rotavirus vaccine is to prevent severe illness that can lead to dehydration in infants and young children in both developed and developing countries. These studies led to the concept that a multivalent vaccine that represented each of the four epidemiologically important VP7 serotypes might be necessary to induce protection in young infants, the target population for vaccination. Human-animal rotavirus reassortants whose gene encoding VP7 was derived from their human rotavirus parent but whose remaining genes were derived from the animal rotavirus parent were developed as vaccine candidates. The greatest experience with a multivalent vaccine to date has been gained with the quadrivalent preparation containing RRV (VP7 serotype 3) and human-RRV reassortants of VP7 serotype 1, 2, and 4 specificity. Preliminary efficacy trial results in the United States have been promising, whereas a study in Peru has shown only limited protection. Human-bovine reassortant vaccines, including a candidate that contains the VP4 gene of a human rotavirus (VP4 serotype 1A), are also being studied.

show abstract

Reactogenicity and Antigenicity of the Rhesus Rotavirus Vaccine in Venezuelan Children

Cited by 42 publications

References 5 publications

Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates

Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates

Rotaviruses: Immunological Determinants of Protection Against Infection and Disease

Rotavirus vaccines: an overview

Contact Info

Product

Resources

About